FP-1039

DRUG2 trials

Sponsors

Five Prime Therapeutics, Inc.

Conditions

Advanced CancerEndometrial Cancers With FGFR2 Mutations

Phase 1

Safety Study of FP-1039 To Treat Cancer

CompletedNCT00687505

Five Prime Therapeutics, Inc.Advanced Cancer

Start: 2008-07-31End: 2011-06-30Updated: 2021-12-13

Phase 2

Study of FP-1039 in Subjects With Endometrial Cancers

WithdrawnNCT01244438

Five Prime Therapeutics, Inc.Endometrial Cancers With FGFR2 Mutations

Start: 2011-01-31End: 2012-12-31Updated: 2021-12-13